Nanobiotix gets FDA fast track status for NBTXR3 to investigate in head and neck cancer

This article was originally published here

The designation has been granted for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, to treat patients with locally advanced head and neck squamous

The post Nanobiotix gets FDA fast track status for NBTXR3 to investigate in head and neck cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply